Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Rhea-AI Summary

Dyadic (NASDAQ: DYAI) announced an OEM distribution agreement with IBT Bioservices on March 16, 2026 to commercialize Dyadic-produced recombinant proteins for research-use-only applications. Initial products include recombinant DNase I and recombinant transferrin (human and bovine), leveraging IBT’s global sales channels to expand market access.

The collaboration complements Dyadic’s manufacturing and portfolio expansion, supports the company’s shift toward product-based revenues, and allows flexibility for future distribution, licensing of production strains, or partner-led manufacturing.

Market Reality Check

Price: $0.7600 Vol: Volume 36,071 is below th...

low vol

$0.7600 Last Close

Volume Volume 36,071 is below the 20-day average of 74,040, indicating muted pre-news trading. low

Technical Shares traded below the 200-day MA of 0.96 with a prior close around 0.76, near the 52-week low of 0.711.

Peers on Argus

DYAI’s modest -0.58% move contrasted with sharper declines in peers like CASI (-...

DYAI’s modest -0.58% move contrasted with sharper declines in peers like CASI (-38.97%), LSB (-20.62%), ANTX (-8.84%), and ESLA (-5.97%), while PLUR was flat, suggesting stock-specific dynamics rather than a coordinated sector move.

Previous Partnership Reports

3 past events · Latest: Dec 17 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Dec 17	Strategic collaboration	Positive	-1.4%	Expanded Fermbox collaboration to manufacture and co-commercialize animal-free proteins.
Dec 15	Commercial agreement	Positive	-9.3%	Opes Diagnostics deal to launch recombinant transferrin and growth factors globally.
Jun 28	Development partnership	Positive	-6.3%	Proliant partnership to develop and commercialize recombinant albumin products.

Pattern Detected

Partnership announcements have historically been followed by negative next-day moves despite their strategic focus.

Recent Company History

Over the past several quarters, Dyadic has repeatedly used partnerships to commercialize its recombinant protein platforms. A Jun 28, 2024 albumin partnership, the Dec 15, 2025 Opes Diagnostics agreement, and the Dec 17, 2025 Fermbox expansion all targeted scaled manufacturing and broader distribution. Each carried a positive commercialization narrative but was followed by single-day share declines between roughly -1% and -9%. Today’s IBT Bioservices OEM distribution deal fits this pattern of expanding routes to market for animal-free proteins and media components.

Historical Comparison

-5.6% avg move · In the past 18 months, three partnership announcements averaged a -5.64% next-day move. The new IBT ...

partnership

-5.6%

Average Historical Move partnership

In the past 18 months, three partnership announcements averaged a -5.64% next-day move. The new IBT OEM distribution deal extends this commercialization pattern in recombinant proteins.

Partnerships have moved from initial recombinant albumin development to broader commercialization of transferrin, growth factors, and multiple animal-free proteins across life science and industrial markets.

Market Pulse Summary

This announcement highlights Dyadic’s next step in commercial execution: an OEM distribution deal wi...

Analysis

This announcement highlights Dyadic’s next step in commercial execution: an OEM distribution deal with IBT to place recombinant DNase I and transferrin into research markets via established channels. It continues a series of partnerships aimed at monetizing animal-free proteins. Recent filings underscore financing tools and Nasdaq compliance constraints, which remain important background risks. Investors may watch how quickly this and prior collaborations translate into recurring product-based revenue and broader portfolio uptake across end markets.

Key Terms

original equipment manufacturer, oem, recombinant protein, research-use-only, +1 more

5 terms

original equipment manufacturer technical

"it has entered into an original equipment manufacturer (“OEM”) distribution agreement"

An original equipment manufacturer (OEM) is a company that designs and builds parts or complete products that other firms sell under their own brand name, like a bakery making cakes that coffee shops rebrand and sell. Investors care because OEMs often win steady, long-term contracts, predictable production volumes and thin but scalable profit margins, so changes in their order book or supply chain can signal future revenue and risk for both the OEM and the brands that rely on it.

oem technical

"In addition to OEM distribution, the collaboration provides flexibility for potential future expansion"

OEM stands for Original Equipment Manufacturer, which is a company that produces parts or components used in the final products made by other companies. For investors, understanding OEMs is important because their performance can impact the supply chain and overall success of major industries, especially those relying on specialized parts. Think of OEMs as the suppliers that provide the building blocks for larger products, like the engine parts for a car.

recombinant protein medical

"Dyadic-produced recombinant protein products will be commercialized through IBT’s established sales channels"

A recombinant protein is a protein produced by inserting the gene that encodes it into a host cell (like bacteria, yeast, or cultured animal cells) so the cell becomes a tiny factory making that protein. For investors, recombinant proteins matter because they form the basis of many medicines, vaccines, and diagnostic tests; their ability to be manufactured reliably, at scale, and under patent or regulatory control affects a biotech product’s commercial potential and risk.

research-use-only regulatory

"with a focus on research-use-only (“RUO”) applications"

Products labeled “research-use-only” are tools, tests, or reagents sold for laboratory experiments and scientific study, not approved for diagnosing, treating, or making clinical decisions about patients. For investors, the label matters because it limits where and how a product can be sold, keeps regulatory burdens lower but also narrows market size and revenue potential until the product is validated and approved for clinical or commercial use — like a prototype that can’t yet be sold in stores.

cell culture medical

"along with additional cell culture–relevant recombinant proteins"

Cell culture is the process of growing living cells in a controlled laboratory environment outside of a whole organism, like keeping a small patch of tissue alive in a petri dish or flask. Investors care because it’s how companies test drug effects, develop biologic medicines and vaccines, and scale manufacturing — think of it as a test kitchen and factory for therapies that reveals whether a product works, is safe, and can be produced reliably.

AI-generated analysis. Not financial advice.

JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer (“OEM”) distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices (“IBT”), a life sciences reagent manufacturer and distributor serving global research markets. Through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT’s established sales channels, expanding market access and supporting Dyadic’s objective of generating ongoing, product-based revenues.

The initial products expected to be offered under the agreement include recombinant DNase I and recombinant transferrin, with a focus on research-use-only (“RUO”) applications. Dyadic expects to offer both human and bovine transferrin, along with additional cell culture–relevant recombinant proteins, as part of a broader and expanding product portfolio.

This relationship complements Dyadic’s recent portfolio and manufacturing expansion initiatives and supports the Company’s ability to commercialize a broader range of recombinant protein products across multiple end markets. By leveraging IBT’s established commercial infrastructure, Dyadic can efficiently place products into the market while continuing to scale manufacturing capabilities and broaden its offerings over time.

“This agreement is a meaningful milestone for Dyadic,” said Joe Hazelton, President and Chief Operating Officer of Dyadic. “It represents an important step in our transition from R&D-driven revenue toward commercial product sales, enabling Dyadic-produced products to reach the market through established global distribution channels. Agreements like this are central to our strategy as we focus on direct sales, OEM relationships, and other commercialization pathways to drive growth and build durable revenue streams over time.”

In addition to OEM distribution, the collaboration provides flexibility for potential future expansion, which could include Dyadic supplying market-ready products for distribution or licensing production strains to support partner-led manufacturing, consistent with Dyadic’s multi-channel commercialization approach.

Dyadic believes this agreement reflects continued progress in advancing from platform development to commercial execution and supports the Company’s long-term objective of translating its technology and manufacturing capabilities into scalable revenue opportunities.

About Dyadic Applied BioSolutions

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.com.

About IBT Bioservices

IBT Bioservices (Integrated BioTherapeutics, LLC d/b/a IBT Bioservices) is a premier provider of specialized life sciences reagents and preclinical contract research services supporting global research in infectious disease, biodefense, and immunology. In addition to manufacturing a comprehensive portfolio of high-quality biological reagents, IBT offers expert CRO services, including custom in vitro assays and in vivo efficacy models designed to accelerate the development of vaccines and therapeutics. Through a robust internal sales organization and an extensive network of authorized distributors, the company ensures the global research community has access to both the critical tools and the technical expertise needed to combat emerging health threats.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic’s clinical trial and interest in its protein production platforms, Dyadic’s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) Dyadic’s history of net losses; (ii) market and regulatory acceptance of Dyadic’s microbial protein production platforms and other technologies; (iii) failure to commercialize Dyadic’s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) Dyadic’s capital needs; (vii) changes in global economic and financial conditions; (viii) Dyadic’s reliance on information technology; (ix) Dyadic’s dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) Dyadic’s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic’s actual results to differ from its current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic’s expectations.

Media contacts:

Dyadic Applied BioSolutions:
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com 

IBT Bioservices:
Siddharth Rohankhedkar
Senior Manager, Business Development
Phone:(240) 454-8934 x 1003
Email: srohan@integratedbiotherapeutics.com 

FAQ

What did Dyadic (DYAI) announce on March 16, 2026 with IBT Bioservices?

Dyadic announced an OEM distribution agreement with IBT to commercialize recombinant proteins through IBT’s channels. According to the company, initial RUO products include recombinant DNase I and human and bovine transferrin to expand product-based revenues.

Which Dyadic recombinant products will IBT Bioservices distribute under the DYAI agreement?

IBT will initially offer recombinant DNase I and recombinant transferrin for RUO use. According to the company, Dyadic expects to offer both human and bovine transferrin and additional cell culture–relevant proteins over time.

How does the DYAI–IBT partnership affect Dyadic’s commercialization strategy?

The partnership broadens market access by using IBT’s established sales channels to place products efficiently. According to the company, it supports Dyadic’s transition from R&D-driven revenue toward commercial product sales and multi-channel commercialization.

Will the Dyadic and IBT collaboration expand beyond OEM distribution for DYAI products?

The agreement provides flexibility for potential expansion into market-ready product supply or licensing production strains for partner-led manufacturing. According to the company, this fits Dyadic’s multi-channel commercialization approach and future scalability goals.

Are the Dyadic (DYAI) products marketed through IBT intended for clinical use?

No, the initial recombinant products are intended for research-use-only (RUO) applications, not clinical use. According to the company, the focus is on RUO recombinant DNase I, transferrin, and additional cell culture–relevant proteins.

What immediate benefits does Dyadic expect from the DYAI OEM distribution deal with IBT?

Dyadic expects expanded market access and more efficient product placement via IBT’s commercial infrastructure. According to the company, the collaboration supports scaling manufacturing and generating ongoing, product-based revenues over time.